{"id":743494,"date":"2025-05-15T19:12:01","date_gmt":"2025-05-15T19:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=743494"},"modified":"2025-05-15T19:12:01","modified_gmt":"2025-05-15T19:12:01","slug":"nonpostoperative-acute-pain-market-poised-for-significant-expansion-by-2034-amid-fda-approvals-and-innovative-therapeutic-pipeline-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonpostoperative-acute-pain-market-poised-for-significant-expansion-by-2034-amid-fda-approvals-and-innovative-therapeutic-pipeline-delveinsight_743494.html","title":{"rendered":"Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsight"},"content":{"rendered":"
\n
\"Non-Postoperative<\/a><\/div>\n
\n
Non-Postoperative Acute Pain Market Insight, Epidemiology, and Market Forecast – DelveInsight<\/div>\n<\/div>\n<\/div>\n
The non-postoperative acute pain treatment market is positioned for substantial growth, driven by a strategic shift from traditional opioid therapies to advanced multimodal analgesia approaches and novel treatment options. Key pharmaceutical companies, including Vertex Pharmaceuticals, H. Lundbeck, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others, are spearheading innovation to address the significant unmet needs in non-postoperative acute pain management.<\/div>\n

DelveInsight’s report titled “Non-Postoperative Acute Pain Market Insight, Epidemiology, and Market Forecast – 2034<\/a><\/strong>” provides a thorough analysis of trends in the non-postoperative acute pain market. It covers market drivers and challenges, historical and projected epidemiology, the current treatment landscape, and emerging therapies across the 7MM, which include the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n

The non-postoperative acute pain market size in the 7MM was valued at USD 3.6 billion in 2023<\/strong>, with significant growth expected at a notable CAGR during the forecast period (2024-2034). This growth is primarily fueled by rising prevalence, enhanced diagnostic capabilities, and the introduction of novel therapeutic options.<\/p>\n

Download the Non-Postoperative Acute Pain Market Forecast Report to understand which factors are driving the Non-Postoperative Acute Pain market @ Non-Postoperative Acute Pain Market Trends<\/a>.<\/strong><\/p>\n

The US represents the largest share<\/strong> of the non-postoperative acute pain market, with approximately 50 million incident cases reported in 2023. Epidemiological data reveal that moderate to severe cases contributed approximately 60% to the total diagnosed cases in the 7MM. Furthermore, pain cases related to migraine and cluster headaches constituted approximately 40% of total diagnosed cases<\/strong> in 2023 in the US, highlighting the significant burden of headache disorders within the acute pain spectrum.<\/p>\n

Discover evolving trends in the Non-Postoperative Acute Pain patient pool forecasts @ Non-Postoperative Acute Pain Epidemiological Analysis<\/a>.<\/strong><\/p>\n

The current non-postoperative acute pain treatment paradigm has undergone substantial transformation in recent years, with a notable shift away from opioid-based therapies toward multimodal analgesia (MMA) models. NSAIDs continue to play a crucial role in pain management, recognized for their ability to decrease opioid consumption by approximately 50%, positioning them as first-line medications for mild-to-moderate pain. Despite the availability of numerous generic NSAIDs following patent expirations, branded innovations continue to emerge, offering improved delivery systems and enhanced efficacy profiles.<\/p>\n

Among the recently approved medications<\/a><\/strong>, ELYXYB (celecoxib) by Scilex Holding (NASDAQ: SCLX)<\/strong> represents a breakthrough as the first and only ready-to-use oral solution designed for fast and long-lasting migraine relief with COX-2 selectivity. Other significant market entrants include ZAVZPRET (zavegepant) by Pfizer (NYSE: PFE)<\/strong>, the first calcitonin gene-related peptide (CGRP) receptor antagonist available as a nasal spray, and NURTEC ODT by Pfizer\/Biohaven Pharmaceutical (NYSE: BHVN)<\/strong>, expanding treatment options for patients suffering from acute migraines.<\/p>\n

Furthermore, in January 2025, SYMBRAVO (AXS-07) was approved by the FDA<\/strong> for the acute treatment of migraine with or without aura in adults<\/strong>. The drug is a novel oral, rapidly-absorbed, multi-mechanistic investigational medicine combining MoSEIC meloxicam and rizatriptan for the acute treatment of migraine, with patent protection extending to 2036.<\/p>\n

The non-postoperative acute pain therapeutic pipeline shows significant promise, with several advanced candidates in late-stage development. VYEPTI (eptinezumab) by H. Lundbeck A\/S (CPH: HLUN-B)<\/strong>, a monoclonal immunoglobulin G1 antibody that specifically binds to human calcitonin gene-related peptide, is currently in Phase III development for cluster headache following its FDA approval for migraine prevention in adults in February 2020.<\/p>\n

Satsuma Pharmaceuticals (NASDAQ: STSA) is developing STS101<\/strong>, a dihydroergotamine nasal powder, which has demonstrated significant efficacy in providing sustained pain freedom and reduced need for rescue medication. Other notable pipeline candidates include Naltrexone Cetaminophen by Allodynic Therapeutics<\/strong>, further diversifying the therapeutic landscape<\/p>\n

Discover evolving trends in the Non-Postoperative Acute Pain treatment landscape @ Non-Postoperative Acute Pain Recent Developments<\/a>.<\/strong><\/p>\n

According to DelveInsight’s specialists in the field, emerging therapies like STS101 DHE nasal powder<\/strong> have shown significant effectiveness in providing sustained pain relief with lower rescue medication requirements. The FDA’s approval of therapies like EMGALITY for reducing the frequency of episodic cluster headache attacks represents a milestone in addressing previously undertreated acute pain conditions. These developments signal a positive trajectory for patients seeking more effective and targeted pain relief options.<\/p>\n

Despite therapeutic advances, challenges remain in the non-postoperative acute pain landscape, including the need for improved diagnostic accuracy, personalized treatment approaches, and enhanced accessibility to innovative therapies. As the field continues to evolve, increasing focus on biomarker-guided therapy selection and integration of non-pharmacological approaches alongside pharmaceutical interventions will likely reshape treatment strategies, offering improved outcomes for the millions affected by acute pain conditions worldwide.<\/p>\n

The integration of emerging digital health technologies and improved understanding of pain neurobiology is expected to further revolutionize acute pain management, moving toward more personalized, effective, and safer treatment paradigms that significantly enhance patient quality of life while minimizing the risks associated with traditional pain management approaches.<\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Non-Postoperative Acute Pain<\/p>\n

3. Non-Postoperative Acute Pain Competitive Intelligence<\/p>\n

4. Non-Postoperative Acute Pain: Market Overview at a Glance<\/p>\n

5. Non-Postoperative Acute Pain: Disease Background and Overview<\/p>\n

6. Patient Journey<\/p>\n

7. Non-Postoperative Acute Pain Epidemiology and Patient Population<\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Non-Postoperative Acute Pain Unmet Needs<\/p>\n

10. Key Endpoints of Non-Postoperative Acute Pain Treatment<\/p>\n

11. Non-Postoperative Acute Pain Marketed Products<\/p>\n

12. Non-Postoperative Acute Pain Emerging Therapies<\/p>\n

13. Non-Postoperative Acute Pain: Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

16. Access and Reimbursement Overview of Non-Postoperative Acute Pain<\/p>\n

17. KOL Views<\/p>\n

18. Non-Postoperative Acute Pain Market Drivers<\/p>\n

19. Non-Postoperative Acute Pain Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Arpit Anand
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Non-Postoperative Acute Pain Market Insight, Epidemiology, and Market Forecast – DelveInsight The non-postoperative acute pain treatment market is positioned for substantial growth, driven by a strategic shift from traditional opioid therapies to advanced multimodal analgesia approaches and novel treatment options. … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-743494","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/743494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=743494"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/743494\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=743494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=743494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=743494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}